Pharma Journalist -

Astellas Pharma and Seattle Genetics announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug…
Read More...

Shire plc and NanoMedSyn announced that the companies have entered into a preclinical research collaboration to evaluate a potential ERT using NanoMedSyn's proprietary synthetic…
Read More...

Teva Pharmaceutical Industries Ltd., announced the launch of a generic version of ALOXI®1 (palonosetron HCI) injection, 0.25 mg/5 mL, in the United States. Palonosetron hydrochloride…
Read More...

The Highly Potent Active Pharmaceutical Ingredients conference will be hosting 2 interactive half day post-conference workshops on the 23rd May, presented by HPAPI Project Services…
Read More...

Prothena Corporation announced a global collaboration with Celgene Corporation to develop new therapies for a broad range of neurodegenerative diseases. The multi-year research and…
Read More...

Regeneron Pharmaceuticals and Alnylam Pharmaceuticals announced a collaboration to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis (NASH) and…
Read More...

Seattle Genetics announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) in combination with chemotherapy in adult patients with…
Read More...

Merck announced the appointment of Jennifer Zachary as general counsel, effective April 16, 2018. Zachary will be responsible for Merck’s global legal, security and aviation, and…
Read More...

Horizon Discovery Group announces that one of the licensees to its Bioproduction cell line technology has used Horizon’s cell line as part of a successful Investigational New Drug (IND)…
Read More...

BIOASIS TECHNOLOGIES announced that Dr. Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE, has been appointed as chair of the board of directors. She takes over from former board chair…
Read More...